Search
Provides real-time visualization and guidance for measuring ventricular septal thickness during septal myectomy surgery
Lexington, MA, April 26, 2024—FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the launch of its first-of-kind OPIE Transducer for on-pump intracardiac echocardiography (OPIE) for septal myectomy. Early clinical users of the OPIE transducer will discuss how the technology helps to evaluate the ventricular septal thickness during septal myectomy surgery by providing real-time imaging visualization during the 104th American Association for Thoracic Surgery (AATS) meeting held April 27-30 in Toronto, ON, Canada.
Traditionally, a cardiothoracic surgeon uses transesophageal echocardiography (TEE) before performing septal myectomy. Currently, TEE cannot be leveraged during cardiac bypass surgery. Instead, a surgeon views the patient’s septal thickness via TEE prior to performing open-heart surgery and would trim the septum – if necessary – without real-time guidance. However, with OPIE, a thin transducer is passed into the heart during the myectomy where images of the patient’s septal thickness can be seen in real-time.
A study featuring Fujifilm’s OPIE Transducer highlights that the system provides established imaging to aid in septal myectomy procedures compared to TEE and transthoracic echocardiogram (TTE). Real-time measurements of the interventricular septal thickness are crucial during septal myectomy to avoid creating a ventricular septal defect while resecting enough myocardium. The OPIE transducer is compatible with Fujifilm’s premium ultrasound system, the ARIETTA Precision.
“During septal myectomy, it is critical to correctly measure the patient’s septal thickness because it can directly impact the patient’s care pathway,” said Hideyuki Honda, vice president, ultrasound solutions, FUJIFILM Healthcare Americas Corporation. “Every day we pride ourselves on delivering what we believe is the highest quality ultrasound solutions, arming cardiologists and cardiothoracic surgeons alike with the visualization they need to eliminate guess work in the operating room. Early clinical results of our OPIE Transducer during a high-risk procedure like cardiac bypass surgery are impressive, and we’re proud that the technology is proving to provide high-quality, real-time feedback for the surgeon.”
During the AATS annual meeting, Daniel G. Swistel, MD, Professor, Department of Cardiothoracic Surgery at NYU Grossman School of Medicine and Nicolas Smedira, MD, Cardiothoracic Surgeon with the Cleveland Clinic, will discuss their clinical experience using Fujifilm’s ARIETTA Precision with the OPIE transducer during open heart surgery, and explain the advantages of cardiothoracic surgeons having real-time visualization to help assist with septal myectomy surgical procedures. Their joint presentation is taking place on Saturday, April 27th from 6:20-6:40 pm at the Product Technology Theatre (Theatre 2).
In addition to the OPIE Transducer and ARIETTA Precision Ultrasound system, Fujifilm will also demonstrate the ELUXEO Vision, an FDA-designated Breakthrough Device that provides real-time tissue oxygenation visualization for laparoscopic and endoscopic applications at AATS booth #431A. Also during the AATS annual meeting, Takeo Fujita, MD, PhD, FACS, Director, Division of Digestive Surgical Oncology, Esophageal Surgery with the National Cancer Center Hospital East, Japan, will discuss how the ELUXEO Vision helps assess tissue oxygen saturation and its correlation with indocyanine green in the gastric conduit during thoracic esophagectomy on Monday, April 29 from 9:00-9:30 am at the Tech Theater Session II.
*The OPIE transducer is currently available in the United States and is pending regulatory requirements in Canada.
About FUJIFILM Healthcare Americas Corporation
FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis and treatment of diseases. Fujifilm’s innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery. The award-winning Synapse® Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record. Fujifilm’s AI initiative, REiLI®, combines Fujifilm’s rich image-processing heritage with cutting-edge AI innovations to inspire clinical confidence and combat burnout. The In-Vitro Diagnostic portfolio provides the gold standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts. For more information, please visit healthcaresolutions-us.fujifilm.com.
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver “Value from Innovation” in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030, click here. For the year ended March 31, 2023, the company had global revenues of approximately 2.9 trillion yen (21 billion USD at an exchange rate of 134 yen/dollar). For more information, please visit: www.fujifilmholdings.com.
Contact:
Marissa Confredo
914-789-8526